Efficacy and safety of canagliflozin 300 mg in overweight and obese type 2 diabetes mellitus patients in a real-world setting: COLOR study

Background and Aims: To assess the efficacy and safety of canagliflozin (CANA, 300 mg/d) in overweight and obese patients with type 2 diabetes mellitus (T2DM). Methods: In a single centre, retrospective, observational study, we included overweight or obese patients with T2DM who had HbA1c >7% and re...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Pankaj Aneja, Gaurav Bhalla, Neeti Parvesh, Kunal Aneja, Kashish Aneja
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Wolters Kluwer Medknow Publications 2019-01-01
Schriftenreihe:	Indian Journal of Endocrinology and Metabolism
Schlagworte:	Canagliflozin HbA1c India obese type 2 diabetes mellitus
Online-Zugang:	http://www.ijem.in/article.asp?issn=2230-8210;year=2019;volume=23;issue=3;spage=307;epage=311;aulast=Aneja
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!